Latest Content

Randomized clinical trials increasingly support mental health apps as scalable, cost-efficient tools for managing depression and anxiety.

Patients hospitalized for bronchiectasis exacerbations face higher mortality, longer stays, and greater costs than those with COPD or asthma.

An improvement in ophthalmological knowledge was seen compared with older large language models and ophthalmology trainees.

Rozanolixizumab shows promise in treating triple-seronegative myasthenia gravis, offering hope for patients with limited treatment options.

Long-term nitrogen dioxide exposure raises ovarian cancer risk, underscoring the need for stricter air quality measures.

Semaglutide and tirzepatide led to the most weight loss across 22 trials, while liraglutide remains a cost-effective alternative as its patent expires.

Men who have sex with men (MSM) expressed interest in both monthly oral pills and injections every 6 months to prevent HIV.

Plozasiran gains FDA approval as the first treatment for familial chylomicronemia syndrome based on phase 3 PALISADE data.

The FDA approved epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a promising fixed-duration treatment option for patients after their first relapse.